{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:22Z","timestamp":1793061322559,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102933","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:57:22Z","timestamp":1784818642000},"page":"102933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice"],"prefix":"10.1016","volume":"7","author":[{"given":"Bingfeng","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuening","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-2864","authenticated-orcid":false,"given":"HaiFang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102933_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430028","article-title":"Updates on Systemic Therapy for Hepatocellular Carcinoma","volume":"44","author":"Ntellas","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.xcrm.2026.102933_bib2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","article-title":"AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma","volume":"162","author":"Su","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2026.102933_bib3","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102933_bib4","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102933_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/JHC.S401639","article-title":"Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3\/4 Ligands in Hepatocellular Carcinoma","volume":"10","author":"Zhou","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.xcrm.2026.102933_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-022-01266-8","article-title":"Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses","volume":"15","author":"Zuo","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102933_bib7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.31279","article-title":"Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?","volume":"73","author":"Lu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2026.102933_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13073-019-0636-8","article-title":"Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma","volume":"11","author":"L\u00f6ffler","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12896-021-00683-w","article-title":"Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope","volume":"21","author":"Aslan","year":"2021","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102933_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13046-020-01781-x","article-title":"Dexosomes as a cell-free vaccine for cancer immunotherapy","volume":"39","author":"Nikfarjam","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102933_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-020-01278-3","article-title":"Exosome-based immunotherapy: a promising approach for cancer treatment","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102933_bib13","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.29829","article-title":"Fluorescent peptide highlights micronodules in murine hepatocellular carcinoma models and humans in vitro","volume":"68","author":"Jing","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2026.102933_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.20101354","article-title":"High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses","volume":"209","author":"Yang","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib15","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/s41467-020-15569-2","article-title":"Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice","volume":"11","author":"Zuo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102933_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat0195","article-title":"Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy","volume":"10","author":"Gao","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/pro.70032","article-title":"The multifaceted role of XCL1 in health and disease","volume":"34","author":"Syed","year":"2025","journal-title":"Protein Sci."},{"key":"10.1016\/j.xcrm.2026.102933_bib18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","article-title":"A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity","volume":"41","author":"Meiser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102933_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1019198","article-title":"Cross-presentation of cutaneous melanoma antigen by migratory XCR1(+)CD103(-) and XCR1(+)CD103(+) dendritic cells","volume":"4","author":"Wylie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.xcrm.2026.102933_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.immuni.2009.08.027","article-title":"Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells","volume":"31","author":"Dorner","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102933_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.xcrm.2026.102933_bib22","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3389\/fimmu.2018.02806","article-title":"Structure-Function Relationship of XCL1 Used for in vivo Targeting of Antigen Into XCR1(+) Dendritic Cells","volume":"9","author":"Kroczek","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102933_bib23","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.3389\/fimmu.2018.02775","article-title":"A Highly Active Form of XCL1\/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8(+) T Cells","volume":"9","author":"Matsuo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102933_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158340","article-title":"Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer","volume":"22","author":"Brandum","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102933_bib25","first-page":"1","article-title":"Dendritic cell subsets and locations","volume":"348","author":"Balan","year":"2019","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.xcrm.2026.102933_bib26","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102933_bib27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2026.102933_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.xcrm.2026.102933_bib29","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3892\/ijo.2013.1793","article-title":"Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide","volume":"42","author":"Iwama","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.xcrm.2026.102933_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102933_bib32","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1257","article-title":"Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination","volume":"11","author":"Badovinac","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib33","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1038\/s41467-025-60657-w","article-title":"Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies","volume":"16","author":"Damei","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102933_bib34","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102933_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102933_bib36","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1172\/JCI81137","article-title":"Dendritic cell-derived exosomes for cancer therapy","volume":"126","author":"Pitt","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102933_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.102933_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-21-1258","article-title":"NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy","volume":"29","author":"Pinter","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102933_bib39","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1038\/s41467-023-42334-y","article-title":"Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis","volume":"14","author":"Soeda","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102933_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12943-024-02001-2","article-title":"Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA(+) B cells","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102933_bib41","article-title":"MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2026.102933_bib43","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.cell.2025.06.004","article-title":"Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity","volume":"188","author":"Du","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102933_bib44","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102933_bib45","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102933_bib46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102933_bib47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102933_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113250","article-title":"Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine","volume":"152","author":"Xia","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.xcrm.2026.102933_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CJI.0b013e3181fe535b","article-title":"Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma","volume":"34","author":"Viaud","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2026.102933_bib50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jhep.2017.05.019","article-title":"Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models","volume":"67","author":"Lu","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2026.102933_bib51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like Tyrosine Kinase 3\/FLT3: From Basic Science to Clinical Implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.xcrm.2026.102933_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073778","article-title":"Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options","volume":"23","author":"Sas","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102933_bib53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2026.102933_bib54","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.immuni.2019.05.013","article-title":"CXCR3-CXCL9: It's All in the Tumor","volume":"50","author":"Humblin","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102933_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2019.02.016","article-title":"CXCL11 promotes self-renewal and tumorigenicity of alpha2delta1(+) liver tumor-initiating cells through CXCR3\/ERK1\/2 signaling","volume":"449","author":"Zhang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2026.102933_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2025.08.023","article-title":"CCL5: An emerging key target and progress in the targeted therapy of hepatocellular carcinoma","volume":"187","author":"Liu","year":"2025","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.xcrm.2026.102933_bib57","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3748\/wjg.v25.i24.2977","article-title":"Immunotherapy for hepatocellular carcinoma: Current and future","volume":"25","author":"Johnston","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2026.102933_bib58","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2026.102933_bib59","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1016\/j.ymthe.2023.10.021","article-title":"Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy","volume":"31","author":"Zhang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102933_bib60","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26893","article-title":"Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma","volume":"59","author":"Hong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2026.102933_bib61","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102933_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008888","article-title":"Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin","volume":"12","author":"Zheng","year":"2024","journal-title":"J. Immunother. Cancer"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:28:07Z","timestamp":1793060887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003502"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102933","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102933"}}